Patient Guide: Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 6 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06209736
Status: 🟢 Enrolling Now
Condition: C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis
Phase: PHASE2

Where You Can Participate

This study is available at 6 locations across the country.

Top locations include:
  • • Kaunas,
  • • Vilnius,
  • • Auckland,
  • • And 3 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN - Join Clinical Trial NCTNCT06209736

How to Join This Clinical Trial - NCTNCT06209736

Learn how to participate in this PHASE2 trial studying an investigational therapy for C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis
Treatment Being Tested
Investigational treatment
Study Phase
PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06209736 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 6 locations. Find a study site near you:

Clinical Research Site

Kaunas, - Lithuania

Status: RECRUITING

Clinical Research Site

Vilnius, - Lithuania

Status: RECRUITING

Clinical Research Site

Auckland, - New Zealand

Status: RECRUITING

Clinical Research Site

Łódź, - Poland

Status: RECRUITING

Clinical Research Site

Leicester, - United Kingdom

Status: RECRUITING

Clinical Research Site

Newcastle Upon Tyne, - United Kingdom

Status: RECRUITING

How to Enroll in This Study

To learn more about participating in this PHASE2 clinical trial for C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships